
LINK . SPRINGER . COM {
}
Title:
Interim analysis of the efficiency and safety of neoadjuvant PD-1 inhibitor (sintilimab) combined with chemotherapy (nab-paclitaxel and carboplatin) in potentially resectable stage IIIA/IIIB non-small cell lung cancer: a single-arm, phase 2 trial | Journal of Cancer Research and Clinical Oncology
Description:
Introduction While some clinical studies have shown that PD-1 and PD-L1 can also be an effective neoadjuvant treatment for early-stage non-small cell lung cancer (NSCLC), no evidence has been available for the use of the PD-1 inhibitor sintilimab combined with chemotherapy as a neoadjuvant treatment for potentially resectable NSCLC in the Chinese population. Methods This prospective, single-center, single-arm, phase 2 clinical trial (registration number: NCT04326153) included treatment-naive patients with potentially resectable NSCLC (stage IIIA/IIIB) who received sintilimab plus nab-paclitaxel and carboplatin for two to three cycles before systematic nodal dissection 30 to 45 days after neoadjuvant treatment. After surgery, patients needed to complete two cycles of adjuvant chemoimmunotherapy (sintilimab + nab-paclitaxel + carboplatin). The primary endpoint was disease-free survival rate at 24 months, whereas secondary endpoints included major pathological response (MPR) and pathologic complete response (pCR) rates, the proportion of patients who achieved tumor downstaging, overall survival, objective response rate (ORR), and adverse effects. PD-L1 status before and after treatment was also determined. Results Among the 20 patients who received neoadjuvant chemoimmunotherapy, 16 underwent radical resection. The disease control rate and ORR were 90% and 70%, respectively. Among the 16 patients who underwent surgery, 10 (62.5%) and 5 (31.25%) achieved MPR and pCR, respectively. Squamous cell NSCLC exhibited superior response rates compared to adenocarcinoma (pCR 35.7% vs. 0%). Moreover, 14 patients (70%) experienced grade 1 or 2 neoadjuvant treatment-related adverse events (TRAEs), whereas 6 (30%) experienced grade 3 TRAEs. Bronchopleural fistula (BPF) was found in the current study as an adverse reaction of concern. The rate of BPF was 20% (4/20), of which three patients were in grade 1–2, and one patient died. The occurrence of BPF had no significant correlation with basic disease history, nutritional status, anemia, hypoalbuminemia, surgical procedure, pathological remission, and PD-L1 expression. However, during neoadjuvant treatment, no adverse events prompted dose reduction, treatment discontinuation, surgery delay, or death. Although PD-L1 expression may change after chemoimmunotherapy, no regular pattern was noted. PD-L1 expression, neither at baseline nor after neoadjuvant chemoimmunotherapy, was associated with pathological remission. Conclusions The current study found similar ORR, slightly lower MPR and pCR rates, and lower grade 3 TRAEs among patients with potentially resectable stage IIIA/IIIB NSCLC compared to the NADIM trial, as well as a greater ORR, MPR rate, pCR rate, and grade 3 TRAEs compared to Gao’s study involving sintilimab for Chinese patients with resectable stage IA–IIIB NSCLC. Though neoadjuvant chemoimmunotherapy had been found to promote a high risk of BPF for patients with stage IIIA/IIIB disease, it offered greater potential for radical cure. Therefore, the current study suggests that neoadjuvant chemoimmunotherapy can be a safe approach in increasing the efficiency of treatment and hopefully improving the prognosis of patients with potentially resectable locally advanced NSCLC.
Website Age:
28 years and 1 months (reg. 1997-05-29).
Matching Content Categories {📚}
- Education
- Health & Fitness
- Science
Content Management System {📝}
What CMS is link.springer.com built with?
Custom-built
No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.
Traffic Estimate {📈}
What is the average monthly size of link.springer.com audience?
🌠 Phenomenal Traffic: 5M - 10M visitors per month
Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.
check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush
How Does Link.springer.com Make Money? {💸}
The income method remains a mystery to us.
While many websites aim to make money, others are created to share knowledge or showcase creativity. People build websites for various reasons. This could be one of them. Link.springer.com could be getting rich in stealth mode, or the way it's monetizing isn't detectable.
Keywords {🔍}
article, cancer, pubmed, google, scholar, lung, neoadjuvant, patients, cell, resectable, nonsmall, cas, chemotherapy, nsclc, response, oncol, data, treatment, phase, sintilimab, thorac, central, clinical, stage, trial, study, surgery, pathological, adverse, nonsmallcell, clin, management, singlearm, chemoimmunotherapy, rate, bronchopleural, fistula, ann, surg, jilin, potentially, liu, survival, pcr, events, advanced, access, privacy, cookies, content,
Topics {✒️}
stage iiia-n2 egfr-mutant month download article/chapter small-cell lung cancer stage iiia/iiib disease william wn jr small-cell lung cancers t-cell checkpoint inhibitors stage ii-iii stage iiia/iiib disease-free survival rate phase ii trial included treatment-naive patients advanced squamous nsclc lung cancer surgery major pathological response resectable lung cancer clinical oncology aims potentially resectable nsclc lung cancer resection resected lung cancer full article pdf privacy choices/manage cookies open window thoracostomy kewei ma systematic meta-analysis william wn zhiguang yang resectable locally advanced objective response rate pathologic complete response low-dose radiotherapy article sun stage iii sintilimab + nab-paclitaxel + carboplatin common terminology criteria response evaluation criteria neoadjuvant checkpoint blockade basic disease history advanced solid tumors disease control rate european economic area shi qiu code availability french database epithor erlotinib versus gemcitabine pathological effect interpretation clinical risk model neoadjuvant pd-1 inhibitor article journal xiaobo ma
Questions {❓}
- Chatwal MS, Tanvetyanon T (2018) Combination chemotherapy and immunotherapy in metastatic non-small cell lung cancer: a setback for personalized medicine?
Schema {🗺️}
WebPage:
mainEntity:
headline:Interim analysis of the efficiency and safety of neoadjuvant PD-1 inhibitor (sintilimab) combined with chemotherapy (nab-paclitaxel and carboplatin) in potentially resectable stage IIIA/IIIB non-small cell lung cancer: a single-arm, phase 2 trial
description:While some clinical studies have shown that PD-1 and PD-L1 can also be an effective neoadjuvant treatment for early-stage non-small cell lung cancer (NSCLC), no evidence has been available for the use of the PD-1 inhibitor sintilimab combined with chemotherapy as a neoadjuvant treatment for potentially resectable NSCLC in the Chinese population. This prospective, single-center, single-arm, phase 2 clinical trial (registration number: NCT04326153) included treatment-naive patients with potentially resectable NSCLC (stage IIIA/IIIB) who received sintilimab plus nab-paclitaxel and carboplatin for two to three cycles before systematic nodal dissection 30 to 45 days after neoadjuvant treatment. After surgery, patients needed to complete two cycles of adjuvant chemoimmunotherapy (sintilimab + nab-paclitaxel + carboplatin). The primary endpoint was disease-free survival rate at 24 months, whereas secondary endpoints included major pathological response (MPR) and pathologic complete response (pCR) rates, the proportion of patients who achieved tumor downstaging, overall survival, objective response rate (ORR), and adverse effects. PD-L1 status before and after treatment was also determined. Among the 20 patients who received neoadjuvant chemoimmunotherapy, 16 underwent radical resection. The disease control rate and ORR were 90% and 70%, respectively. Among the 16 patients who underwent surgery, 10 (62.5%) and 5 (31.25%) achieved MPR and pCR, respectively. Squamous cell NSCLC exhibited superior response rates compared to adenocarcinoma (pCR 35.7% vs. 0%). Moreover, 14 patients (70%) experienced grade 1 or 2 neoadjuvant treatment-related adverse events (TRAEs), whereas 6 (30%) experienced grade 3 TRAEs. Bronchopleural fistula (BPF) was found in the current study as an adverse reaction of concern. The rate of BPF was 20% (4/20), of which three patients were in grade 1–2, and one patient died. The occurrence of BPF had no significant correlation with basic disease history, nutritional status, anemia, hypoalbuminemia, surgical procedure, pathological remission, and PD-L1 expression. However, during neoadjuvant treatment, no adverse events prompted dose reduction, treatment discontinuation, surgery delay, or death. Although PD-L1 expression may change after chemoimmunotherapy, no regular pattern was noted. PD-L1 expression, neither at baseline nor after neoadjuvant chemoimmunotherapy, was associated with pathological remission. The current study found similar ORR, slightly lower MPR and pCR rates, and lower grade 3 TRAEs among patients with potentially resectable stage IIIA/IIIB NSCLC compared to the NADIM trial, as well as a greater ORR, MPR rate, pCR rate, and grade 3 TRAEs compared to Gao’s study involving sintilimab for Chinese patients with resectable stage IA–IIIB NSCLC. Though neoadjuvant chemoimmunotherapy had been found to promote a high risk of BPF for patients with stage IIIA/IIIB disease, it offered greater potential for radical cure. Therefore, the current study suggests that neoadjuvant chemoimmunotherapy can be a safe approach in increasing the efficiency of treatment and hopefully improving the prognosis of patients with potentially resectable locally advanced NSCLC.
datePublished:2022-02-22T00:00:00Z
dateModified:2022-02-22T00:00:00Z
pageStart:819
pageEnd:831
sameAs:https://doi.org/10.1007/s00432-021-03896-w
keywords:
Non-small cell lung cancer
Neoadjuvant
Chemoimmunotherapy
Sintilimab
Oncology
Cancer Research
Internal Medicine
Hematology
image:
https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00432-021-03896-w/MediaObjects/432_2021_3896_Fig1_HTML.png
https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00432-021-03896-w/MediaObjects/432_2021_3896_Fig2_HTML.png
https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00432-021-03896-w/MediaObjects/432_2021_3896_Fig3_HTML.png
https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00432-021-03896-w/MediaObjects/432_2021_3896_Fig4_HTML.png
isPartOf:
name:Journal of Cancer Research and Clinical Oncology
issn:
1432-1335
0171-5216
volumeNumber:149
type:
Periodical
PublicationVolume
publisher:
name:Springer Berlin Heidelberg
logo:
url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
type:ImageObject
type:Organization
author:
name:Chao Sun
affiliation:
name:The First Hospital of Jilin University
address:
name:Cancer Center, The First Hospital of Jilin University, Changchun, China
type:PostalAddress
type:Organization
type:Person
name:Yunpeng Liu
affiliation:
name:The First Hospital of Jilin University
address:
name:Thoracic Surgery Department, The First Hospital of Jilin University, Changchun, China
type:PostalAddress
type:Organization
type:Person
name:Peng Zhang
affiliation:
name:The First Hospital of Jilin University
address:
name:Thoracic Surgery Department, The First Hospital of Jilin University, Changchun, China
type:PostalAddress
type:Organization
type:Person
name:Xu Wang
affiliation:
name:The First Hospital of Jilin University
address:
name:Cancer Center, The First Hospital of Jilin University, Changchun, China
type:PostalAddress
type:Organization
type:Person
name:Yinghui Xu
affiliation:
name:The First Hospital of Jilin University
address:
name:Cancer Center, The First Hospital of Jilin University, Changchun, China
type:PostalAddress
type:Organization
type:Person
name:Xingyu Lin
affiliation:
name:The First Hospital of Jilin University
address:
name:Thoracic Surgery Department, The First Hospital of Jilin University, Changchun, China
type:PostalAddress
type:Organization
type:Person
name:Xiaobo Ma
affiliation:
name:The First Hospital of Jilin University
address:
name:Pathological Department, The First Hospital of Jilin University, Changchun, China
type:PostalAddress
type:Organization
type:Person
name:Ye Guo
affiliation:
name:The First Hospital of Jilin University
address:
name:Cancer Center, The First Hospital of Jilin University, Changchun, China
type:PostalAddress
type:Organization
type:Person
name:Shi Qiu
affiliation:
name:The First Hospital of Jilin University
address:
name:Cancer Center, The First Hospital of Jilin University, Changchun, China
type:PostalAddress
type:Organization
type:Person
name:Guoguang Shao
affiliation:
name:The First Hospital of Jilin University
address:
name:Thoracic Surgery Department, The First Hospital of Jilin University, Changchun, China
type:PostalAddress
type:Organization
type:Person
name:Zhiguang Yang
affiliation:
name:The First Hospital of Jilin University
address:
name:Thoracic Surgery Department, The First Hospital of Jilin University, Changchun, China
type:PostalAddress
type:Organization
email:[email protected]
type:Person
name:Kewei Ma
url:http://orcid.org/0000-0003-2987-576X
affiliation:
name:The First Hospital of Jilin University
address:
name:Cancer Center, The First Hospital of Jilin University, Changchun, China
type:PostalAddress
type:Organization
email:[email protected]
type:Person
isAccessibleForFree:
hasPart:
isAccessibleForFree:
cssSelector:.main-content
type:WebPageElement
type:ScholarlyArticle
context:https://schema.org
ScholarlyArticle:
headline:Interim analysis of the efficiency and safety of neoadjuvant PD-1 inhibitor (sintilimab) combined with chemotherapy (nab-paclitaxel and carboplatin) in potentially resectable stage IIIA/IIIB non-small cell lung cancer: a single-arm, phase 2 trial
description:While some clinical studies have shown that PD-1 and PD-L1 can also be an effective neoadjuvant treatment for early-stage non-small cell lung cancer (NSCLC), no evidence has been available for the use of the PD-1 inhibitor sintilimab combined with chemotherapy as a neoadjuvant treatment for potentially resectable NSCLC in the Chinese population. This prospective, single-center, single-arm, phase 2 clinical trial (registration number: NCT04326153) included treatment-naive patients with potentially resectable NSCLC (stage IIIA/IIIB) who received sintilimab plus nab-paclitaxel and carboplatin for two to three cycles before systematic nodal dissection 30 to 45 days after neoadjuvant treatment. After surgery, patients needed to complete two cycles of adjuvant chemoimmunotherapy (sintilimab + nab-paclitaxel + carboplatin). The primary endpoint was disease-free survival rate at 24 months, whereas secondary endpoints included major pathological response (MPR) and pathologic complete response (pCR) rates, the proportion of patients who achieved tumor downstaging, overall survival, objective response rate (ORR), and adverse effects. PD-L1 status before and after treatment was also determined. Among the 20 patients who received neoadjuvant chemoimmunotherapy, 16 underwent radical resection. The disease control rate and ORR were 90% and 70%, respectively. Among the 16 patients who underwent surgery, 10 (62.5%) and 5 (31.25%) achieved MPR and pCR, respectively. Squamous cell NSCLC exhibited superior response rates compared to adenocarcinoma (pCR 35.7% vs. 0%). Moreover, 14 patients (70%) experienced grade 1 or 2 neoadjuvant treatment-related adverse events (TRAEs), whereas 6 (30%) experienced grade 3 TRAEs. Bronchopleural fistula (BPF) was found in the current study as an adverse reaction of concern. The rate of BPF was 20% (4/20), of which three patients were in grade 1–2, and one patient died. The occurrence of BPF had no significant correlation with basic disease history, nutritional status, anemia, hypoalbuminemia, surgical procedure, pathological remission, and PD-L1 expression. However, during neoadjuvant treatment, no adverse events prompted dose reduction, treatment discontinuation, surgery delay, or death. Although PD-L1 expression may change after chemoimmunotherapy, no regular pattern was noted. PD-L1 expression, neither at baseline nor after neoadjuvant chemoimmunotherapy, was associated with pathological remission. The current study found similar ORR, slightly lower MPR and pCR rates, and lower grade 3 TRAEs among patients with potentially resectable stage IIIA/IIIB NSCLC compared to the NADIM trial, as well as a greater ORR, MPR rate, pCR rate, and grade 3 TRAEs compared to Gao’s study involving sintilimab for Chinese patients with resectable stage IA–IIIB NSCLC. Though neoadjuvant chemoimmunotherapy had been found to promote a high risk of BPF for patients with stage IIIA/IIIB disease, it offered greater potential for radical cure. Therefore, the current study suggests that neoadjuvant chemoimmunotherapy can be a safe approach in increasing the efficiency of treatment and hopefully improving the prognosis of patients with potentially resectable locally advanced NSCLC.
datePublished:2022-02-22T00:00:00Z
dateModified:2022-02-22T00:00:00Z
pageStart:819
pageEnd:831
sameAs:https://doi.org/10.1007/s00432-021-03896-w
keywords:
Non-small cell lung cancer
Neoadjuvant
Chemoimmunotherapy
Sintilimab
Oncology
Cancer Research
Internal Medicine
Hematology
image:
https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00432-021-03896-w/MediaObjects/432_2021_3896_Fig1_HTML.png
https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00432-021-03896-w/MediaObjects/432_2021_3896_Fig2_HTML.png
https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00432-021-03896-w/MediaObjects/432_2021_3896_Fig3_HTML.png
https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00432-021-03896-w/MediaObjects/432_2021_3896_Fig4_HTML.png
isPartOf:
name:Journal of Cancer Research and Clinical Oncology
issn:
1432-1335
0171-5216
volumeNumber:149
type:
Periodical
PublicationVolume
publisher:
name:Springer Berlin Heidelberg
logo:
url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
type:ImageObject
type:Organization
author:
name:Chao Sun
affiliation:
name:The First Hospital of Jilin University
address:
name:Cancer Center, The First Hospital of Jilin University, Changchun, China
type:PostalAddress
type:Organization
type:Person
name:Yunpeng Liu
affiliation:
name:The First Hospital of Jilin University
address:
name:Thoracic Surgery Department, The First Hospital of Jilin University, Changchun, China
type:PostalAddress
type:Organization
type:Person
name:Peng Zhang
affiliation:
name:The First Hospital of Jilin University
address:
name:Thoracic Surgery Department, The First Hospital of Jilin University, Changchun, China
type:PostalAddress
type:Organization
type:Person
name:Xu Wang
affiliation:
name:The First Hospital of Jilin University
address:
name:Cancer Center, The First Hospital of Jilin University, Changchun, China
type:PostalAddress
type:Organization
type:Person
name:Yinghui Xu
affiliation:
name:The First Hospital of Jilin University
address:
name:Cancer Center, The First Hospital of Jilin University, Changchun, China
type:PostalAddress
type:Organization
type:Person
name:Xingyu Lin
affiliation:
name:The First Hospital of Jilin University
address:
name:Thoracic Surgery Department, The First Hospital of Jilin University, Changchun, China
type:PostalAddress
type:Organization
type:Person
name:Xiaobo Ma
affiliation:
name:The First Hospital of Jilin University
address:
name:Pathological Department, The First Hospital of Jilin University, Changchun, China
type:PostalAddress
type:Organization
type:Person
name:Ye Guo
affiliation:
name:The First Hospital of Jilin University
address:
name:Cancer Center, The First Hospital of Jilin University, Changchun, China
type:PostalAddress
type:Organization
type:Person
name:Shi Qiu
affiliation:
name:The First Hospital of Jilin University
address:
name:Cancer Center, The First Hospital of Jilin University, Changchun, China
type:PostalAddress
type:Organization
type:Person
name:Guoguang Shao
affiliation:
name:The First Hospital of Jilin University
address:
name:Thoracic Surgery Department, The First Hospital of Jilin University, Changchun, China
type:PostalAddress
type:Organization
type:Person
name:Zhiguang Yang
affiliation:
name:The First Hospital of Jilin University
address:
name:Thoracic Surgery Department, The First Hospital of Jilin University, Changchun, China
type:PostalAddress
type:Organization
email:[email protected]
type:Person
name:Kewei Ma
url:http://orcid.org/0000-0003-2987-576X
affiliation:
name:The First Hospital of Jilin University
address:
name:Cancer Center, The First Hospital of Jilin University, Changchun, China
type:PostalAddress
type:Organization
email:[email protected]
type:Person
isAccessibleForFree:
hasPart:
isAccessibleForFree:
cssSelector:.main-content
type:WebPageElement
["Periodical","PublicationVolume"]:
name:Journal of Cancer Research and Clinical Oncology
issn:
1432-1335
0171-5216
volumeNumber:149
Organization:
name:Springer Berlin Heidelberg
logo:
url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
type:ImageObject
name:The First Hospital of Jilin University
address:
name:Cancer Center, The First Hospital of Jilin University, Changchun, China
type:PostalAddress
name:The First Hospital of Jilin University
address:
name:Thoracic Surgery Department, The First Hospital of Jilin University, Changchun, China
type:PostalAddress
name:The First Hospital of Jilin University
address:
name:Thoracic Surgery Department, The First Hospital of Jilin University, Changchun, China
type:PostalAddress
name:The First Hospital of Jilin University
address:
name:Cancer Center, The First Hospital of Jilin University, Changchun, China
type:PostalAddress
name:The First Hospital of Jilin University
address:
name:Cancer Center, The First Hospital of Jilin University, Changchun, China
type:PostalAddress
name:The First Hospital of Jilin University
address:
name:Thoracic Surgery Department, The First Hospital of Jilin University, Changchun, China
type:PostalAddress
name:The First Hospital of Jilin University
address:
name:Pathological Department, The First Hospital of Jilin University, Changchun, China
type:PostalAddress
name:The First Hospital of Jilin University
address:
name:Cancer Center, The First Hospital of Jilin University, Changchun, China
type:PostalAddress
name:The First Hospital of Jilin University
address:
name:Cancer Center, The First Hospital of Jilin University, Changchun, China
type:PostalAddress
name:The First Hospital of Jilin University
address:
name:Thoracic Surgery Department, The First Hospital of Jilin University, Changchun, China
type:PostalAddress
name:The First Hospital of Jilin University
address:
name:Thoracic Surgery Department, The First Hospital of Jilin University, Changchun, China
type:PostalAddress
name:The First Hospital of Jilin University
address:
name:Cancer Center, The First Hospital of Jilin University, Changchun, China
type:PostalAddress
ImageObject:
url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
name:Chao Sun
affiliation:
name:The First Hospital of Jilin University
address:
name:Cancer Center, The First Hospital of Jilin University, Changchun, China
type:PostalAddress
type:Organization
name:Yunpeng Liu
affiliation:
name:The First Hospital of Jilin University
address:
name:Thoracic Surgery Department, The First Hospital of Jilin University, Changchun, China
type:PostalAddress
type:Organization
name:Peng Zhang
affiliation:
name:The First Hospital of Jilin University
address:
name:Thoracic Surgery Department, The First Hospital of Jilin University, Changchun, China
type:PostalAddress
type:Organization
name:Xu Wang
affiliation:
name:The First Hospital of Jilin University
address:
name:Cancer Center, The First Hospital of Jilin University, Changchun, China
type:PostalAddress
type:Organization
name:Yinghui Xu
affiliation:
name:The First Hospital of Jilin University
address:
name:Cancer Center, The First Hospital of Jilin University, Changchun, China
type:PostalAddress
type:Organization
name:Xingyu Lin
affiliation:
name:The First Hospital of Jilin University
address:
name:Thoracic Surgery Department, The First Hospital of Jilin University, Changchun, China
type:PostalAddress
type:Organization
name:Xiaobo Ma
affiliation:
name:The First Hospital of Jilin University
address:
name:Pathological Department, The First Hospital of Jilin University, Changchun, China
type:PostalAddress
type:Organization
name:Ye Guo
affiliation:
name:The First Hospital of Jilin University
address:
name:Cancer Center, The First Hospital of Jilin University, Changchun, China
type:PostalAddress
type:Organization
name:Shi Qiu
affiliation:
name:The First Hospital of Jilin University
address:
name:Cancer Center, The First Hospital of Jilin University, Changchun, China
type:PostalAddress
type:Organization
name:Guoguang Shao
affiliation:
name:The First Hospital of Jilin University
address:
name:Thoracic Surgery Department, The First Hospital of Jilin University, Changchun, China
type:PostalAddress
type:Organization
name:Zhiguang Yang
affiliation:
name:The First Hospital of Jilin University
address:
name:Thoracic Surgery Department, The First Hospital of Jilin University, Changchun, China
type:PostalAddress
type:Organization
email:[email protected]
name:Kewei Ma
url:http://orcid.org/0000-0003-2987-576X
affiliation:
name:The First Hospital of Jilin University
address:
name:Cancer Center, The First Hospital of Jilin University, Changchun, China
type:PostalAddress
type:Organization
email:[email protected]
PostalAddress:
name:Cancer Center, The First Hospital of Jilin University, Changchun, China
name:Thoracic Surgery Department, The First Hospital of Jilin University, Changchun, China
name:Thoracic Surgery Department, The First Hospital of Jilin University, Changchun, China
name:Cancer Center, The First Hospital of Jilin University, Changchun, China
name:Cancer Center, The First Hospital of Jilin University, Changchun, China
name:Thoracic Surgery Department, The First Hospital of Jilin University, Changchun, China
name:Pathological Department, The First Hospital of Jilin University, Changchun, China
name:Cancer Center, The First Hospital of Jilin University, Changchun, China
name:Cancer Center, The First Hospital of Jilin University, Changchun, China
name:Thoracic Surgery Department, The First Hospital of Jilin University, Changchun, China
name:Thoracic Surgery Department, The First Hospital of Jilin University, Changchun, China
name:Cancer Center, The First Hospital of Jilin University, Changchun, China
WebPageElement:
isAccessibleForFree:
cssSelector:.main-content
External Links {🔗}(152)
- What's the total monthly financial gain of https://www.springernature.com/gp/authors?
- Income figures for https://link.springernature.com/home/
- Discover the revenue of https://order.springer.com/public/cart
- Get to know https://submission.nature.com/new-submission/432/3's earnings
- Profit of https://orcid.org/0000-0003-2987-576X
- How much income is https://www.springernature.com/gp/librarians/licensing/agc/journals earning monthly?
- https://doi.org/10.3390%2Fjcm7060153's financial summary
- http://scholar.google.com/scholar_lookup?&title=An%20update%20on%20predictive%20biomarkers%20for%20treatment%20selection%20in%20non-small%20cell%20lung%20cancer&journal=J%20Clin%20Med&doi=10.3390%2Fjcm7060153&volume=20167&issue=6&publication_year=2018&author=Ahmadzada%2CT&author=Kao%2CS&author=Reid%2CG's total income per month
- How much revenue does https://doi.org/10.1093%2Fannonc%2Fmdy540 generate?
- How much profit does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=30566590 generate?
- Monthly income for http://scholar.google.com/scholar_lookup?&title=Safety%20and%20efficacy%20of%20nivolumab%20in%20combination%20with%20S-1%2Fcapecitabine%20plus%20oxaliplatin%20in%20patients%20with%20previously%20untreated%2C%20unresectable%2C%20advanced%2C%20or%20recurrent%20gastric%2Fgastroesophageal%20junction%20cancer%3A%20interim%20results%20of%20a%20randomized%2C%20phase%20II%20trial%20%28ATTRACTION-4%29&journal=Ann%20Oncol&doi=10.1093%2Fannonc%2Fmdy540&volume=30&issue=2&pages=250-258&publication_year=2019&author=Boku%2CN&author=Ryu%2CMH&author=Kato%2CK
- How much does https://doi.org/10.3322%2Fcaac.21609 pull in monthly?
- How much does http://scholar.google.com/scholar_lookup?&title=Global%20cancer%20statistics%202018%3A%20GLOBOCAN%20estimates%20of%20incidence%20and%20mortality%20worldwide%20for%2036%20cancers%20in%20185%20countries%20%28vol%2068%2C%20pg%20394%2C%202018%29&journal=Ca-a%20Cancer%20J%20Clin&doi=10.3322%2Fcaac.21609&volume=70&issue=4&pages=313-313&publication_year=2020&author=Bray%2CF&author=Ferlay%2CJ&author=Soerjomataram%2CI gross monthly?
- What is the monthly revenue of https://doi.org/10.1200%2FJCO.2019.37.15_suppl.8504?
- Get to know what's the income of http://scholar.google.com/scholar_lookup?&title=Neoadjuvant%20nivolumab%20%28N%29%20or%20nivolumab%20plus%20ipilimumab%20%28NI%29%20for%20resectable%20non-small%20cell%20lung%20cancer%20%28NSCLC%29%3A%20clinical%20and%20correlative%20results%20from%20the%20NEOSTAR%20study&journal=J%20Clin%20Oncol&doi=10.1200%2FJCO.2019.37.15_suppl.8504&volume=37&issue=15_suppl&pages=8504-8504&publication_year=2019&author=Cascone%2CT&author=William%2CWN&author=Weissferdt%2CA
- What's the monthly money flow for https://doi.org/10.1016%2Fj.athoracsur.2017.03.038?
- What's the financial gain of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=28838509?
- Learn how profitable http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5572805 is on a monthly basis
- Check the income stats for http://scholar.google.com/scholar_lookup?&title=Initial%20experience%20with%20lung%20cancer%20resection%20after%20treatment%20with%20T-cell%20checkpoint%20inhibitors&journal=Ann%20Thorac%20Surg&doi=10.1016%2Fj.athoracsur.2017.03.038&volume=104&issue=3&pages=e217-e218&publication_year=2017&author=Chaft%2CJE&author=Hellmann%2CMD&author=Velez%2CMJ
- Find out how much https://doi.org/10.21037%2Ftlcr.2018.07.15 earns monthly
- How much does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=30393603 pull in?
- What's the financial gain of http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6193911?
- What's the profit of http://scholar.google.com/scholar_lookup?&title=Combination%20chemotherapy%20and%20immunotherapy%20in%20metastatic%20non-small%20cell%20lung%20cancer%3A%20a%20setback%20for%20personalized%20medicine%3F&journal=Transl%20Lung%20Cancer%20Res&doi=10.21037%2Ftlcr.2018.07.15&volume=7&pages=S208-S210&publication_year=2018&author=Chatwal%2CMS&author=Tanvetyanon%2CT?
- What are the total earnings of https://doi.org/10.1056%2FNEJMoa1716078?
- How much does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=29658848 earn?
- See how much http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6223617 makes per month
- Financial intake of http://scholar.google.com/scholar_lookup?&title=Neoadjuvant%20PD-1%20blockade%20in%20resectable%20lung%20cancer&journal=N%20Engl%20J%20Med&doi=10.1056%2FNEJMoa1716078&volume=378&issue=21&pages=1976-1986&publication_year=2018&author=Forde%2CPM&author=Chaft%2CJE&author=Smith%2CKN
- Discover the revenue of https://doi.org/10.1056%2FNEJMoa1801005
- Get to know http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=29658856's earnings
- How much does http://scholar.google.com/scholar_lookup?&title=Pembrolizumab%20plus%20chemotherapy%20in%20metastatic%20non-small-cell%20lung%20cancer&journal=N%20Engl%20J%20Med&doi=10.1056%2FNEJMoa1801005&volume=378&issue=22&pages=2078-2092&publication_year=2018&author=Gandhi%2CL&author=Rodr%C3%ADguez-Abreu%2CD&author=Gadgeel%2CS make?
- How much does https://doi.org/10.1016%2Fj.jtho.2020.01.017 gross monthly?
- See how much http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=32036071 makes per month
- How much does http://scholar.google.com/scholar_lookup?&title=Neoadjuvant%20PD-1%20inhibitor%20%28Sintilimab%29%20in%20NSCLC&journal=J%20Thorac%20Oncol&doi=10.1016%2Fj.jtho.2020.01.017&volume=15&issue=5&pages=816-826&publication_year=2020&author=Gao%2CS&author=Li%2CN&author=Gao%2CS pull in?
- How much money does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=32803520 make?
- http://scholar.google.com/scholar_lookup?&title=Striving%20toward%20improved%20outcomes%20for%20surgically%20resectable%20non-small%20cell%20lung%20cancer%3A%20the%20promise%20and%20challenges%20of%20neoadjuvant%20immunotherapy&journal=Curr%20Oncol%20Rep&doi=10.1007%2Fs11912-020-00969-w&volume=22&issue=11&pages=109-109&publication_year=2020&author=Gentzler%2CRD&author=Riley%2CDO&author=Martin%2CLW's financial summary
- What's the financial outcome of https://doi.org/10.1016%2FS1470-2045%2813%2970334-6?
- How much does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=24384493 make?
- How profitable is http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4734624?
- Revenue of http://scholar.google.com/scholar_lookup?&title=Pathological%20response%20after%20neoadjuvant%20chemotherapy%20in%20resectable%20non-small-cell%20lung%20cancers%3A%20proposal%20for%20the%20use%20of%20major%20pathological%20response%20as%20a%20surrogate%20endpoint&journal=Lancet%20Oncol&doi=10.1016%2FS1470-2045%2813%2970334-6&volume=15&issue=1&pages=e42-50&publication_year=2014&author=Hellmann%2CMD&author=Chaft%2CJE&author=William%2CWN
- What's the revenue for https://doi.org/10.1038%2Fs41586-019-1922-8?
- How much revenue does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=31942075 produce monthly?
- What's the revenue for http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8762581?
- What is the monthly revenue of http://scholar.google.com/scholar_lookup?&title=B%20cells%20and%20tertiary%20lymphoid%20structures%20promote%20immunotherapy%20response&journal=Nature&doi=10.1038%2Fs41586-019-1922-8&volume=577&pages=549-555&publication_year=2020&author=Helmink%2CBA&author=Reddy%2CSM&author=Gao%2CJ?
- How much revenue does https://doi.org/10.1016%2Fj.athoracsur.2013.04.050 produce monthly?
- How much does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=23782644 pull in?
- What's the monthly income of http://scholar.google.com/scholar_lookup?&title=A%20clinical%20risk%20model%20for%20the%20evaluation%20of%20bronchopleural%20fistula%20in%20non-small%20cell%20lung%20cancer%20after%20pneumonectomy&journal=Ann%20Thorac%20Surg&doi=10.1016%2Fj.athoracsur.2013.04.050&volume=96&issue=2&pages=419-424&publication_year=2013&author=Hu%2CXF&author=Duan%2CL&author=Jiang%2CGN?
- Discover the revenue of https://doi.org/10.1016%2Fj.athoracsur.2009.06.024
- What are the earnings of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=19853117?
- How much money does http://scholar.google.com/scholar_lookup?&title=Risk%20factor%20comparison%20and%20clinical%20analysis%20of%20early%20and%20late%20bronchopleural%20fistula%20after%20non-small%20cell%20lung%20cancer%20surgery&journal=Ann%20Thorac%20Surg&doi=10.1016%2Fj.athoracsur.2009.06.024&volume=88&issue=5&pages=1589-1593&publication_year=2009&author=Jichen%2CQV&author=Chen%2CG&author=Jiang%2CG make?
- Get to know https://doi.org/10.1093%2Fjjco%2Fhyw037's earnings
- What is the monthly revenue of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=27052116?
- Get to know what's the income of http://scholar.google.com/scholar_lookup?&title=Neoadjuvant%20therapy%20and%20risk%20of%20bronchopleural%20fistula%20after%20lung%20cancer%20surgery%3A%20a%20systematic%20meta-analysis%20of%2014%20912%20patients&journal=Jpn%20J%20Clin%20Oncol&doi=10.1093%2Fjjco%2Fhyw037&volume=46&issue=6&pages=534-546&publication_year=2016&author=Li%2CS&author=Fan%2CJ&author=Liu%2CJ
- What's the revenue for https://doi.org/10.1002%2Fijc.32366?
- What's the monthly income of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=31018251?
- How much does http://scholar.google.com/scholar_lookup?&title=PD-%20%28L%291%20inhibitors%20vs.%20chemotherapy%20vs.%20their%20combination%20in%20front-line%20treatment%20for%20NSCLC%3A%20an%20indirect%20comparison&journal=Int%20J%20Cancer&doi=10.1002%2Fijc.32366&volume=145&pages=3011-3021&publication_year=2019&author=Liang%2CH&author=Liu%2CZ&author=Cai%2CX rake in every month?
- Discover the revenue of https://doi.org/10.1002%2Fcpt.810
- How much money does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=28786099 generate?
- http://scholar.google.com/scholar_lookup?&title=Current%20landscape%20of%20targeted%20therapy%20in%20lung%20cancer&journal=Clin%20Pharmacol%20Ther&doi=10.1002%2Fcpt.810&volume=102&issue=5&pages=757-764&publication_year=2017&author=Mayekar%2CMK&author=Bivona%2CTG income
- http://scholar.google.com/scholar_lookup?&title=Bronchopleural%20fistula%20after%20pneumonectomy%3A%20risk%20factors%20and%20management%2C%20focusing%20on%20open%20window%20thoracostomy&journal=J%20Thorac%20Cardiovasc%20Surg&volume=S0022%E2%80%935223&issue=17&pages=31189-31193&publication_year=2017&author=Mazzella%2CA&author=Pardolesi%2CA&author=Maisonneuve%2CP's financial summary
- How much revenue does https://doi.org/10.1016%2Fj.athoracsur.2005.07.078 produce monthly?
- How much does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=16427825 pull in monthly?
- Check the income stats for http://scholar.google.com/scholar_lookup?&title=Video-assisted%20thoracic%20surgery%20lobectomy%3A%20experience%20with%201100%20cases&journal=Ann%20Thorac%20Surg&doi=10.1016%2Fj.athoracsur.2005.07.078&volume=81&pages=421-425&publication_year=2006&author=McKenna%2CRJ&author=Houck%2CW&author=Fuller%2CCB
- How much revenue does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=28814907 generate?
- How much cash flow does http://scholar.google.com/scholar_lookup?&title=New%20prognostic%20biomarkers%20and%20therapeutic%20effect%20of%20bevacizumab%20for%20patients%20with%20non-small-cell%20lung%20cancer&journal=Lung%20Cancer%28Auckl%29&volume=8&pages=91-99&publication_year=2017&author=Niki%2CM&author=Yokoi%2CT&author=Kurata%2CT have monthly?
- What's the monthly money flow for https://doi.org/10.1016%2FS0140-6736%2813%2962159-5?
- How much does http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4022989 pull in monthly?
- What is the monthly revenue of http://scholar.google.com/scholar_lookup?&title=Preoperative%20chemotherapy%20for%20non-small-cell%20lung%20cancer%3A%20a%20systematic%20review%20and%20meta-analysis%20of%20individual%20participant%20data&journal=Lancet&doi=10.1016%2FS0140-6736%2813%2962159-5&volume=383&issue=9928&pages=1561-1571&publication_year=2014?
- Profit of https://doi.org/10.1097%2F01.sla.0000234892.79056.63
- Find out how much http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=16926568 earns monthly
- Income figures for http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1856541
- Income figures for http://scholar.google.com/scholar_lookup?&title=Thoracoscopic%20lobectomy%20is%20a%20safe%20and%20versatile%20procedure%3A%20experience%20with%20500%20consecutive%20patients&journal=Ann%20Surg&doi=10.1097%2F01.sla.0000234892.79056.63&volume=244&pages=420-425&publication_year=2006&author=Onaitis%2CMW&author=Petersen%2CRP&author=Balderson%2CSS
- What's the revenue for https://doi.org/10.1097%2FJTO.0b013e318247504a?
- Profit of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=22481232
- Learn about the earnings of http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3465940
- What's the monthly income of http://scholar.google.com/scholar_lookup?&title=Histopathologic%20response%20criteria%20predict%20survival%20of%20patients%20with%20resected%20lung%20cancer%20after%20neoadjuvant%20chemotherapy&journal=J%20Thorac%20Oncol&doi=10.1097%2FJTO.0b013e318247504a&volume=7&issue=5&pages=825-832&publication_year=2012&author=Pataer%2CA&author=Kalhor%2CN&author=Correa%2CAM?
- How much does https://doi.org/10.1016%2Fj.athoracsur.2015.06.026 earn?
- How much revenue does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=26303974 bring in?
- Check the income stats for http://scholar.google.com/scholar_lookup?&title=A%20predictive%20score%20for%20bronchopleural%20fistula%20established%20using%20the%20French%20database%20epithor&journal=Ann%20Thorac%20Surg&doi=10.1016%2Fj.athoracsur.2015.06.026&volume=101&issue=1&pages=287-293&publication_year=2016&author=Pforr%2CA&author=Pages%2CPB&author=Baste%2CJM
- How much does https://doi.org/10.1016%2FS1470-2045%2820%2930453-8 pull in monthly?
- Learn how profitable http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=32979984 is on a monthly basis
- How much does http://scholar.google.com/scholar_lookup?&title=Neoadjuvant%20chemotherapy%20and%20nivolumab%20in%20resectable%20non-small-cell%20lung%20cancer%20%28NADIM%29%3A%20an%20open-label%2C%20multicentre%2C%20single-arm%2C%20phase%202%20trial&journal=Lancet%20Oncol&doi=10.1016%2FS1470-2045%2820%2930453-8&volume=21&issue=11&pages=1413-1422&publication_year=2020&author=Provencio%2CM&author=Nadal%2CE&author=Insa%2CA bring in each month?
- What's the revenue for https://doi.org/10.1378%2Fchest.12-2360?
- Find out how much http://scholar.google.com/scholar_lookup?&title=Treatment%20of%20stage%20III%20non-small%20cell%20lung%20cancer%20diagnosis%20and%20management%20of%20lung%20cancer%2C%203rd%20ed%3A%20American%20college%20of%20chest%20physicians%20evidence-based%20clinical%20practice%20guidelines&journal=Chest&doi=10.1378%2Fchest.12-2360&volume=143&issue=5&pages=E314-E340&publication_year=2013&author=Ramnath%2CN&author=Dilling%2CTJ&author=Harris%2CLJ earns monthly
- Get to know what's the income of https://doi.org/10.1016%2FS1470-2045%2820%2930140-6
- What's the total monthly financial gain of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=32386568?
- http://scholar.google.com/scholar_lookup?&title=Neoadjuvant%20atezolizumab%20and%20chemotherapy%20in%20patients%20with%20resectable%20non-small%20cell%20lung%20cancer%3A%20an%20open-label%2C%20multicentre%20single-arm%2C%20phase%202%20trial&journal=Lancet%20Oncol&doi=10.1016%2FS1470-2045%2820%2930140-6&volume=21&issue=6&pages=786-795&publication_year=2020&author=Shu%2CCA&author=Gainor%2CJF&author=Awad%2CMM's financial summary
- How much revenue does https://doi.org/10.1016%2Fj.jtho.2016.05.024 bring in?
- What's the income generated by http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=27296106 each month?
- What's the income of http://scholar.google.com/scholar_lookup?&title=Clinicopathologic%20features%20of%20advanced%20squamous%20NSCLC&journal=J%20Thorac%20Oncol&doi=10.1016%2Fj.jtho.2016.05.024&volume=11&issue=9&pages=1411-1422&publication_year=2016&author=Socinski%2CMA&author=Obasaju%2CC&author=Gandara%2CD?
- What's the monthly income of https://doi.org/10.1056%2FNEJMoa1716948?
- Discover the revenue of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=29863955
- Monthly income for http://scholar.google.com/scholar_lookup?&title=Atezolizumab%20for%20first-line%20treatment%20of%20metastatic%20nonsquamous%20NSCLC&journal=N%20Engl%20J%20Med&doi=10.1056%2FNEJMoa1716948&volume=378&pages=2288-2301&publication_year=2018&author=Socinski%2CMA&author=Jotte%2CRM&author=Cappuzzo%2CF
- Earnings of https://doi.org/10.1126%2Fscience.aax0182
- What are the total earnings of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=32001626?
- What's the financial intake of http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7789854?
- What's the financial outcome of http://scholar.google.com/scholar_lookup?&title=Neoadjuvant%20checkpoint%20blockade%20for%20cancer%20immunotherapy&journal=Science&doi=10.1126%2Fscience.aax0182&volume=367&publication_year=2020&author=Topalian%2CSL&author=Taube%2CJM&author=Pardoll%2CDM?
- How much does https://doi.org/10.1097%2FJTO.0b013e3182774108 make?
- Get to know what's the income of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=23287849
- What's the financial outcome of http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3549050?
- How much does http://scholar.google.com/scholar_lookup?&title=Computed%20tomography%20RECIST%20assessment%20of%20histopathologic%20response%20and%20prediction%20of%20survival%20in%20patients%20with%20resectable%20non-small-cell%20lung%20cancer%20after%20neoadjuvant%20chemotherapy&journal=J%20Thorac%20Oncol&doi=10.1097%2FJTO.0b013e3182774108&volume=8&issue=2&pages=222-228&publication_year=2013&author=William%2CWN&author=Pataer%2CA&author=Kalhor%2CN pull in monthly?
- Revenue of https://doi.org/10.1200%2FJCO.2018.36.15_suppl.e15125
- What's http://scholar.google.com/scholar_lookup?&title=A%20first-in-human%20phase%201a%20trial%20of%20sintilimab%20%28IBI308%29%2C%20a%20monoclonal%20antibody%20targeting%20programmed%20death-1%20%28PD-1%29%2C%20in%20Chinese%20patients%20with%20advanced%20solid%20tumors&journal=J%20Clin%20Oncol&doi=10.1200%2FJCO.2018.36.15_suppl.e15125&volume=36&issue=15&publication_year=2018&author=Xu%2CJ-M&author=Jia%2CR&author=Wang%2CY's gross income?
- What's the revenue for https://doi.org/10.1200%2FJCO.19.00075?
- Earnings of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=31194613
- What's the income generated by http://scholar.google.com/scholar_lookup?&title=Erlotinib%20versus%20gemcitabine%20plus%20cisplatin%20as%20neoadjuvant%20treatment%20of%20stage%20IIIA-N2%20EGFR-mutant%20non-small-cell%20lung%20cancer%20%28EMERGING-CTONG%201103%29%3A%20a%20randomized%20phase%20II%20study&journal=J%20Clin%20Oncol&doi=10.1200%2FJCO.19.00075&volume=37&issue=25&pages=2235-2245&publication_year=2019&author=Zhong%2CWZ&author=Chen%2CKN&author=Chen%2CC each month?
- See how much https://citation-needed.springer.com/v2/references/10.1007/s00432-021-03896-w?format=refman&flavour=references makes per month
- Learn about the earnings of https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Chao%20Sun
- What's the revenue for https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Chao%20Sun%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en?
- Profit of https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Yunpeng%20Liu
- How much income does https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Yunpeng%20Liu%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en have?
- How much money does https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Peng%20Zhang make?
- How profitable is https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Peng%20Zhang%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en?
- What's the financial gain of https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Xu%20Wang?
- Monthly income for https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Xu%20Wang%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en
- How much does https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Yinghui%20Xu gross monthly?
- What's the monthly money flow for https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Yinghui%20Xu%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en?
- How much money does https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Xingyu%20Lin generate?
- How much does https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Xingyu%20Lin%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en rake in every month?
- Find out how much https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Xiaobo%20Ma earns monthly
- Explore the financials of https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Xiaobo%20Ma%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en
- Learn about the earnings of https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Ye%20Guo
- How much does https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Ye%20Guo%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en rake in every month?
- How much does https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Shi%20Qiu pull in monthly?
- How much does https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Shi%20Qiu%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en gross monthly?
- How much money does https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Guoguang%20Shao generate?
- How much does https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Guoguang%20Shao%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en make?
- Earnings of https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Zhiguang%20Yang
- How much does https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Zhiguang%20Yang%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en generate monthly?
- Explore the financials of https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Kewei%20Ma
- https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Kewei%20Ma%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en's financial summary
- How much does https://static-content.springer.com/esm/art%3A10.1007%2Fs00432-021-03896-w/MediaObjects/432_2021_3896_MOESM1_ESM.gif net monthly?
- How much revenue does https://static-content.springer.com/esm/art%3A10.1007%2Fs00432-021-03896-w/MediaObjects/432_2021_3896_MOESM2_ESM.gif bring in?
- Get to know what's the income of https://static-content.springer.com/esm/art%3A10.1007%2Fs00432-021-03896-w/MediaObjects/432_2021_3896_MOESM3_ESM.docx
- How much revenue does https://s100.copyright.com/AppDispatchServlet?title=Interim%20analysis%20of%20the%20efficiency%20and%20safety%20of%20neoadjuvant%20PD-1%20inhibitor%20%28sintilimab%29%20combined%20with%20chemotherapy%20%28nab-paclitaxel%20and%20carboplatin%29%20in%20potentially%20resectable%20stage%20IIIA%2FIIIB%20non-small%20cell%20lung%20cancer%3A%20a%20single-arm%2C%20phase%202%20trial&author=Chao%20Sun%20et%20al&contentID=10.1007%2Fs00432-021-03896-w©right=The%20Author%28s%29%2C%20under%20exclusive%20licence%20to%20Springer-Verlag%20GmbH%20Germany%2C%20part%20of%20Springer%20Nature&publication=0171-5216&publicationDate=2022-02-22&publisherName=SpringerNature&orderBeanReset=true bring in?
- What's https://crossmark.crossref.org/dialog/?doi=10.1007/s00432-021-03896-w's gross income?
- Check the income stats for https://citation-needed.springer.com/v2/references/10.1007/s00432-021-03896-w?format=refman&flavour=citation
- How much money does https://authorservices.springernature.com/go/sn/?utm_source=SNLinkfooter&utm_medium=Web&utm_campaign=SNReferral generate?
- What is the earnings of https://www.springernature.com/gp/open-research/about/the-fundamentals-of-open-access-and-open-research?
- How much does https://www.springernature.com/gp/products net monthly?
- What's the financial outcome of https://www.springernature.com/gp/librarians?
- What's the revenue for https://www.springernature.com/gp/societies?
- How much income is https://www.springernature.com/gp/partners earning monthly?
- Check the income stats for https://www.springer.com/
- See how much https://www.nature.com/ makes per month
- Check the income stats for https://www.biomedcentral.com/
- How much revenue does https://www.palgrave.com/ generate?
- What's the financial gain of https://www.apress.com/?
- Explore the financials of https://www.springernature.com/gp/legal/ccpa
- How much profit is https://www.springernature.com/gp/info/accessibility making per month?
- Earnings of https://support.springernature.com/en/support/home
- How much does https://support.springernature.com/en/support/solutions/articles/6000255911-subscription-cancellations pull in monthly?
- How much revenue does https://www.springernature.com/ generate?
Analytics and Tracking {📊}
- Google Tag Manager
Libraries {📚}
- Clipboard.js
- Prism.js
- Video.js
CDN Services {📦}
- Crossref